Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis.
暂无分享,去创建一个
M. Humbert | D. Furst | C. Denton | M. Matucci-Cerinic | O. Distler | J. Seibold | C. Opitz | D. Pittrow | L. Rubin | P. Nash | I. Foeldvari | F. Behrens | D. Huscher
[1] M. Mayes,et al. Development of a provisional core set of response measures for clinical trials of systemic sclerosis , 2007, Annals of the rheumatic diseases.
[2] R. Barst,et al. Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease , 2007, Annals of the rheumatic diseases.
[3] M. Humbert,et al. Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis. , 2006, Rheumatology.
[4] R. Barst,et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. , 2006, Journal of the American College of Cardiology.
[5] M. Humbert,et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. , 2005, Arthritis and rheumatism.
[6] O. Sitbon,et al. Bosentan therapy for pulmonary arterial hypertension. , 2005, Future cardiology.
[7] T. Fleming,et al. Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.
[8] M. Dougados,et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis , 2005, Annals of the rheumatic diseases.
[9] W. Taylor. Preliminary identification of core domains for outcome studies in psoriatic arthritis using Delphi methods , 2005, Annals of the rheumatic diseases.
[10] A. Torbicki,et al. [Guidelines on diagnosis and treatment of pulmonary arterial hypertension]. , 2005, Revista espanola de cardiologia.
[11] Horst Olschewski,et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. , 2004, European heart journal.
[12] D. Mccrory,et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.
[13] W. Seeger,et al. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[14] A. Torbicki,et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. , 2004, Journal of the American College of Cardiology.
[15] R. Naeije,et al. End points in pulmonary arterial hypertension: the way forward , 2004, European Respiratory Journal.
[16] R. Dixon,et al. Sitaxsentan therapy for pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.
[17] K. Wasserman,et al. Erratum: Beraprost therapy for pulmonary arterial hypertension (Journal of the American College of Cardiology (2003) 41 (2119-2125)) , 2003 .
[18] M. Suarez‐Almazor,et al. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. , 2003, The Journal of rheumatology.
[19] K. Wasserman,et al. Beraprost therapy for pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.
[20] S. Kimmel,et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. , 2003, Chest.
[21] W. Seeger,et al. Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.
[22] M. Humbert,et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of the American College of Cardiology.
[23] S. Rich,et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.
[24] D. Badesch,et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.
[25] D. Badesch,et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[26] N. Bellamy. Clinimetric concepts in outcome assessment: the OMERACT filter. , 1999, The Journal of rheumatology.
[27] P. Tugwell,et al. The OMERACT filter for Outcome Measures in Rheumatology. , 1998, The Journal of rheumatology.
[28] M Abu-Shakra,et al. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. , 1996, British journal of rheumatology.
[29] Robert C. Kohberger,et al. Cluster Analysis (3rd ed.) , 1994 .
[30] P. Bateson,et al. Measuring behaviour: Analysis and interpretation of data , 1993 .
[31] Roberta M. Roth,et al. A workshop approach to acquiring knowledge from single and multiple experts , 1990, SIGBDP '90.
[32] G. W. Milligan,et al. An examination of the effect of six types of error perturbation on fifteen clustering algorithms , 1980 .
[33] Murray Turoff,et al. The Delphi method : techniques and applications , 1976 .
[34] R. Barst,et al. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. , 2007, Annals of the rheumatic diseases.
[35] K. C. Lewis. Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist Sitaxsentan , 2007 .
[36] M. Cheitlin. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension , 2006 .
[37] Richard N. Shiffman,et al. Metadata-driven Delphi rating on the Internet , 2005, Comput. Methods Programs Biomed..
[38] Avid,et al. BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .
[39] D. Badesch,et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. , 2000, Annals of internal medicine.
[40] Roberta M. Roth,et al. A Delphi approach to acquiring knowledge from single and multiple experts , 1990, SIGBDP '90.
[41] Shirley A. Olsen,et al. Group planning and problem-solving methods in engineering management , 1982 .